Cancer sometimes involves processes that should only occur in the embryo being mistakenly reactivated in adult cells. Researchers at the Postgraduate Medical School at the University of Surrey have exploited this to develop a novel therapeutic strategy. This has led to the development of a new drug, HXR9 that blocks the activity of a group of genes known as the HOX family. [click link for full article]
More...